Nektar reports Q4 adjusted EPS (15c), consensus (19c)

Reports Q4 revenue $29.2M, consensus $36.66M. “The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 2025,” said Howard Robin, President and CEO of Nektar (NKTR). “With enrollment now complete for the atopic dermatitis and alopecia areata Phase 2b trials, we are on track to report topline data for rezpegaldesleukin in the second quarter and in the fourth quarter of this year, respectively. This program is poised to emerge as the first T regulatory cell treatment option to help the millions of patients battling these chronic autoimmune disorders. We also made progress on our preclinical immunology programs,” continued Robin. “We reported the first data for NKTR-0165, our novel antibody targeting TNFR2, and unveiled a new bispecific antibody, NKTR-0166. We plan to submit the IND for NKTR-0165 in the second half of this year.” Cash and investments in marketable securities on December 31, 2024 were $269.1M as compared to $329.4M at December 31, 2023. Nektar’s cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026.